TY - JOUR
T1 - Estrogen receptor 1 gene as a tumor suppressor gene in hepatocellular carcinoma detected by triple-combination array analysis
AU - Hishida, Mitsuhiro
AU - Nomoto, Shuji
AU - Inokawa, Yoshikuni
AU - Hayashi, Masamichi
AU - Kanda, Mitsuro
AU - Okamura, Yukiyasu
AU - Nishikawa, Yoko
AU - Tanaka, Chie
AU - Kobayashi, Daisuke
AU - Yamada, Suguru
AU - Nakayama, Goro
AU - Fujii, Tsutomu
AU - Sugimoto, Hiroyuki
AU - Koike, Masahiko
AU - Fujiwara, Michitaka
AU - Takeda, Shin
AU - Kodera, Yasuhiro
PY - 2013/7
Y1 - 2013/7
N2 - Hepatocellular carcinoma (HCC) is one of the top five causes of cancer-related deaths worldwide. Recent developments in the treatment of HCC remain insufficient to cure unresectable disease or to prevent HCC. Consistent efforts are, therefore, needed to deepen understanding of pathogenesis of the disease. Genome-wide gene expression profile analyses can now detect various candidate genes that are modified by HCC. We have developed a new technique to identify tumor suppressor genes, triple-combination array analysis, which combines gene expression profiles, single nucleotide polymorphism and methylation arrays to identify genes with altered expression. Using HCC tissue samples, triple-combination array analysis was performed to identify a candidate tumor suppressor gene. Subsequently, samples from 48 HCC patients were subjected to quantitative polymerase chain reaction (qPCR) and methylation-specific PCR to further elucidate clinical relevance of the gene. Estrogen receptor 1 (ESR1) was detected as a candidate tumor suppressor gene. Of the 48 clinical samples, 40 (83.3%) showed ESR1 promoter hypermethylation. In 24 (50%) HCC samples, the expression levels of the ESR1 gene was decreased by >90%. The decreased expression was significantly related to high liver damage score, pathological invasion of the intrahepatic portal vein, the size of tumor (>3 cm in diameter) and hepatitis B virus infection. The present study represents another example that triple-combination array is a convenient technique for detecting genes with altered expression in disease. The ESR1 gene was identified as a candidate tumor suppressor gene in HCC and further validation is warranted.
AB - Hepatocellular carcinoma (HCC) is one of the top five causes of cancer-related deaths worldwide. Recent developments in the treatment of HCC remain insufficient to cure unresectable disease or to prevent HCC. Consistent efforts are, therefore, needed to deepen understanding of pathogenesis of the disease. Genome-wide gene expression profile analyses can now detect various candidate genes that are modified by HCC. We have developed a new technique to identify tumor suppressor genes, triple-combination array analysis, which combines gene expression profiles, single nucleotide polymorphism and methylation arrays to identify genes with altered expression. Using HCC tissue samples, triple-combination array analysis was performed to identify a candidate tumor suppressor gene. Subsequently, samples from 48 HCC patients were subjected to quantitative polymerase chain reaction (qPCR) and methylation-specific PCR to further elucidate clinical relevance of the gene. Estrogen receptor 1 (ESR1) was detected as a candidate tumor suppressor gene. Of the 48 clinical samples, 40 (83.3%) showed ESR1 promoter hypermethylation. In 24 (50%) HCC samples, the expression levels of the ESR1 gene was decreased by >90%. The decreased expression was significantly related to high liver damage score, pathological invasion of the intrahepatic portal vein, the size of tumor (>3 cm in diameter) and hepatitis B virus infection. The present study represents another example that triple-combination array is a convenient technique for detecting genes with altered expression in disease. The ESR1 gene was identified as a candidate tumor suppressor gene in HCC and further validation is warranted.
KW - Estrogen receptor 1
KW - Hepatocellular carcinoma
KW - Methylation
KW - Tumor suppressor genes
UR - http://www.scopus.com/inward/record.url?scp=84879609929&partnerID=8YFLogxK
U2 - 10.3892/ijo.2013.1951
DO - 10.3892/ijo.2013.1951
M3 - 学術論文
C2 - 23695389
AN - SCOPUS:84879609929
SN - 1019-6439
VL - 43
SP - 88
EP - 94
JO - International Journal of Oncology
JF - International Journal of Oncology
IS - 1
ER -